Neurogen Biomarking Virtual Care Ecosystem Cuts Time to Alzheimer’s Intervention by 4.5 Years, AAIC 2025 Presentation Findings ShowProgress in validating in-home blood test, combined with cognitive assessment and specialty virtual care, break through barriers to early detection
Neurogen Biomarking to present novel data on at-home p-tau 217 testing for Alzheimer’s disease at Alzheimer’s Association International Conference® 2025CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking will present novel data on at-home p-tau 217 testing for Alzheimer’s disease at the upcoming Alzheimer’s Association International Conference® (AAIC) in Toronto, Canada. Chief Scientific Officer, Elisabeth Thijssen, PhD will report the results of a study designed to validate remote collection of blood biomarkers for Alzheimer’s disease and related disorders.
Neurogen Announces Partnership with NeuroX, a subsidiary of American TelePhysiciansNeurogen’s Brain Health Care Ecosystem Accelerates Access to Early Detection Technology for Alzheimer’s dementia and Mild Cognitive Impairment
Neurogen Biomarking Announces Collaboration with Linus Health Bringing Easy Access to Cutting-Edge Technology to Support Early Detection of Mild Cognitive Impairment and Dementia due to Alzheimer's Disease
Neurogen Biomarking, the world’s first ecosystem for memory loss with end-to-end patient support and Linus Health, a digital health company focused on transforming brain health for people worldwide, finalized an agreement to integrate Linus Health's scientifically-validated digital cognitive assessments into the Neurogen Biomarking ecosystem.
